- Previous Close
64.20 - Open
64.20 - Bid 64.00 x --
- Ask 64.20 x --
- Day's Range
64.00 - 64.20 - 52 Week Range
24.55 - 66.20 - Volume
21,410,147 - Avg. Volume
6,028,905 - Market Cap (intraday)
345.962M - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.06 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 22, 2023
- 1y Target Est
66.46
Alliance Pharma plc acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.
www.alliancepharmaceuticals.com290
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: APH.L
View More
Performance Overview: APH.L
Trailing total returns as of 3/19/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APH.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APH.L
View MoreValuation Measures
Market Cap
347.04M
Enterprise Value
433.56M
Trailing P/E
--
Forward P/E
12.38
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.90
Price/Book (mrq)
1.56
Enterprise Value/Revenue
2.37
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.34%
Return on Assets (ttm)
5.98%
Return on Equity (ttm)
-13.44%
Revenue (ttm)
183.15M
Net Income Avi to Common (ttm)
-33.58M
Diluted EPS (ttm)
-0.06
Balance Sheet and Cash Flow
Total Cash (mrq)
19.27M
Total Debt/Equity (mrq)
47.46%
Levered Free Cash Flow (ttm)
10.35M
Research Analysis: APH.L
View MoreCompany Insights: APH.L
APH.L does not have Company Insights